xRead - An Update on Immunotherapy in Head and Neck Cancer (November 2025)

Review Clinical Review & Education

Immunotherapy in Head and Neck Squamous Cell Carcinoma

20 . Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. NEngl JMed . 2016;375(19): 1856-1867. doi:10.1056/NEJMoa1602252 21 . Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. OralOncol . 2018;81:45-51. doi:10.1016/j. oraloncology.2018.04.008 22 . Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol .2017; 35(14):1542-1549. doi:10.1200/JCO.2016.70.1524 23 . Cohen EEW, Soulières D, Le Tourneau C, et al; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet .2019;393 (10167):156-167. doi:10.1016/S0140-6736(18)31999-8 24 . Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3study. Lancet . 2019;394(10212):1915-1928. doi:10. 1016/S0140-6736(19)32591-7 25 . Dzienis M, Cundom J, Fuentes CS, et al. Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm phase IV trial. J Clin Oncol .2024;42 (25):2989-2999. doi:10.1200/JCO.23.02625 26 . Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer . 2019;7(1): 184. doi:10.1186/s40425-019-0662-5 27 . Ferris RL, Haddad R, Even C, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. AnnOncol . 2020;31(7):942-950. doi:10.1016/j.annonc.2020.04.001 28 . Psyrri A, Fayette J, Harrington K, et al; KESTREL Investigators. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. AnnOncol . 2023;34(3):262-274. doi:10.1016/j. annonc.2022.12.008 29 . Haddad RI, Harrington K, Tahara M, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J Clin Oncol . 2023;41(12):2166-2180. doi:10. 1200/JCO.22.00332 30 . Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Lancet Oncol . 2021;22(4):450-462. doi:10.1016/ S1470-2045(20)30737-3 31 . Machiels JP, Tao Y, Licitra L, et al; KEYNOTE-412 Investigators. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol . 2024;25(5):572-587. doi:10.1016/S1470-2045(24)00100-1 32 . Bourhis J, Tao Y, Sun X, et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. AnnOncol . 2021;32:S1310. doi:10.1016/j. annonc.2021.08.2112 33 . Haddad R, Wong DJ, Guo Y, et al. IMvoke010: randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). AnnOncol . 2018;29:viii397. doi:10.1093/ annonc/mdy287.074 34 . Motzer RJ, Tannir NM, McDermott DF, et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. NEngl JMed . 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126 35 . Tanaka H, Enokida T, Okano S, et al. Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol . 2023;13:1221352. doi:10.3389/ fonc.2023.1221352 36 . Saddawi-Konefka R, Schokrpur S, Gutkind JS. Let it be: preserving tumor-draining lymph nodes in the era of immuno-oncology. Cancer Cell .2024;42 (6):930-933. doi:10.1016/j.ccell.2024.05.015 37 . Marciscano AE, Ghasemzadeh A, Nirschl TR, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res .2018; 24(20):5058-5071. doi:10.1158/1078-0432.CCR-17 3427 38 . Huang Q, Wu X, Wang Z, et al. The primordial differentiation of tumor-specific memory CD8 + T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell .2022;185 (22):4049-4066.e25. doi:10.1016/j.cell.2022.09.020 39 . Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8 + T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell .2023; 186(6):1127-1143.e18. doi:10.1016/j.cell.2023.02.021 40 . Clump DA, Zandberg DP, Skinner HD, et al. A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN). J Clin Oncol . 2022;40(16) (suppl):6007. doi:10.1200/JCO.2022.40.16_suppl. 6007 41 . Colevas AD, Bahleda R, Braiteh F, et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. AnnOncol . 2018;29(11):2247-2253. doi:10.1093/annonc/mdy411

oropharyngeal cancer. NEngl JMed . 2010;363(1): 24-35. doi:10.1056/NEJMoa0912217 5 . Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol . 2011;29(32):4294-4301. doi:10.1200/JCO.2011. 36.4596 6 . Osazuwa-Peters N, Simpson MC, Zhao L, et al. Suicide risk among cancer survivors: Head and neck versus other cancers. Cancer . 2018;124(20): 4072-4079. doi:10.1002/cncr.31675 7 . Muzaffar J, Bari S, Kirtane K, Chung CH. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers (Basel) . 2021;13(2):338. doi:10. 3390/cancers13020338 8 . Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol . 2015;33(29): 3293-3304. doi:10.1200/JCO.2015.61.1509 9 . Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. NatRev Cancer . 2012;12(4):252-264. doi:10.1038/nrc3239 10 . Pardoll D. Releasing the brakes on antitumor immune response. Science . 1996;271(5256): 1691-1691. doi:10.1126/science.271.5256.1691 11 . Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science . 1996;271(5256):1734-1736. doi:10.1126/science.271.5256.1734 12 . Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEngl JMed . 2010;363(8): 711-723. doi:10.1056/NEJMoa1003466 13 . Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. NatCommun .2020;11 (1):3801. doi:10.1038/s41467-020-17670-y 14 . Riley JL. PD-1 signaling in primary T cells. Immunol Rev . 2009;229(1):114-125. doi:10.1111/j. 1600-065X.2009.00767.x 15 . Parvez A, Choudhary F, Mudgal P, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol . 2023;14:1296341. doi:10. 3389/fimmu.2023.1296341 16 . Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. NEngl JMed . 2008;359(11): 1116-1127. doi:10.1056/NEJMoa0802656 17 . Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol . 2016;17(7):956-965. doi:10.1016/S1470-2045 (16)30066-3 18 . Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. JClin Oncol . 2016;34(32):3838-3845. doi:10.1200/JCO. 2016.68.1478 19 . Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br JCancer . 2018;119(2):153-159. doi:10.1038/s41416-018-0131-9

(Reprinted) JAMA Otolaryngology–Head & Neck Surgery May 2025 Volume 151, Number 5 527

jamaotolaryngology.com

© 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Downloaded from jamanetwork.com by Icahn School of Medicine at Mount Sinai user on 09/02/2025